Avalo Therapeutics Inc (AVTX)vsMerck & Company Inc (MRK)
AVTX
Avalo Therapeutics Inc
$7.17
-3.63%
HEALTHCARE · Cap: $384.53M
MRK
Merck & Company Inc
$149.52
+2.18%
HEALTHCARE · Cap: $368.89B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 114199900% more annual revenue ($67.38B vs $59,000). MRK leads profitability with a 3.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 44/100 (D).
AVTX
Avoid30
out of 100
Grade: F
MRK
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AVTX.
Margin of Safety
-76.6%
Fair Value
$84.66
Current Price
$149.52
$64.86 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 4.5B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Trading at 8.8x book value
4.7% revenue growth
ROE of 7.6% — below average capital efficiency
3.6% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AVTX
The strongest argument for AVTX centers on Price/Book, Debt/Equity.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : AVTX
The primary concerns for AVTX are EPS Growth, Market Cap, Profit Margin.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
AVTX carries more volatility with a beta of 0.69 — expect wider price swings.
MRK is growing revenue faster at 4.7% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (44/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Avalo Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Avalo Therapeutics Inc is a forward-thinking clinical-stage biotechnology company focused on developing transformative therapies for rare and underserved diseases, particularly those related to immunological regulation. With a robust pipeline of proprietary drug candidates, Avalo is dedicated to addressing critical unmet medical needs in areas where effective treatments remain scarce. Leveraging in-depth insights into disease mechanisms alongside a rigorous clinical trial methodology, the company is well-positioned to achieve significant advancements in patient care. Through its patient-centric approach, Avalo not only seeks to improve therapeutic outcomes but also aims to make a substantial impact on the lives of those it serves, establishing itself as a noteworthy player in the biopharmaceutical landscape.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?